Skip to main content

Advertisement

SpringerLink
Log in

A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

The purpose of the present study was to precisely compare both the efficacy and abdominal symptom-related quality of life after treatment with daily minodronate and weekly alendronate in patients with primary postmenopausal osteoporosis. The efficacy of the two drugs was assessed based on improvements in a bone turnover marker, back pain, and gastrointestinal symptoms that impair quality of life, which was assessed using the Izumo scale questionnaire. In the minodronate group, there were no significant changes during the treatment period in the specific scores for heartburn, epigastralgia and epigastric fullness, whereas all of the scores were significantly elevated at some time point after drug administration in the alendronate group. Urinary N-telopeptide of type I collagen (uNTX), a bone resorption marker, and bone-specific alkaline phosphatase, a bone formation marker, significantly decreased in both groups, but decreases in uNTX in the minodronate group was observed significantly earlier compared with those in the alendronate group. The back pain scores, which were obtained using a visual analog scale, were significantly reduced in both groups. However, analgesic effects were detected earlier in the minodronate group. In conclusion, compared with weekly alendronate, daily minodronate improved bone turnover and back pain more promptly without causing upper gastrointestinal symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Anastasilakis AD, Goulis DG, Kita M, Avramidis A (2007) Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Hormones 6:233–341

    PubMed  Google Scholar 

  2. Woo C, Gao G, Wade S, Hochberg MC (2010) Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin 26:1003–1009

    Article  PubMed  Google Scholar 

  3. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259–262

    PubMed  CAS  Google Scholar 

  4. Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA, Risedronate Endoscopy Study Group (2002) 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 29:1965–1974

    PubMed  CAS  Google Scholar 

  5. Lanza FL, Hunt RH, Thomas AB, Provenza JM, Blank MA (2000) Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119:631–638

    Article  PubMed  CAS  Google Scholar 

  6. Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437

    Article  PubMed  CAS  Google Scholar 

  7. Ito M, Sone T, Fukunaga M (2009) Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. J Bone Miner Metab 28:334–341

    Article  PubMed  Google Scholar 

  8. Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44:1078–1084

    Article  PubMed  CAS  Google Scholar 

  9. Kakuta E, Yamashita N, Katsube T, Kushiyama Y, Suetsugu H, Furuta K, Kinoshita Y (2011) Abdominal symptom-related QOL in individuals visiting an outpatient clinic and those attending an annual health check. Intern Med 50:1517–1522

    Article  PubMed  Google Scholar 

  10. Kinoshita Y, Chiba T, The FUTURE Study Group (2011) Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: based on the large-scale survey, FUTURE Study. Intern Med 50:2269–2276

    Article  PubMed  Google Scholar 

  11. Orimo H, Sugioka Y, Fukunaga M, Muto M, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139–150

    Article  Google Scholar 

  12. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee, Japanese Society for Bone Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337

    Article  PubMed  CAS  Google Scholar 

  13. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148

    Article  PubMed  CAS  Google Scholar 

  14. Fukunaga M, Nakamura T, Shiraki M, Kuroda T, Ohta H, Hosoi T, Orimo H (2004) Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab 22:104–110

    Article  PubMed  Google Scholar 

  15. Peter CP, Handt LK, Smith SM (1998) Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 43:1998–2002

    Article  PubMed  CAS  Google Scholar 

  16. Peter CP, Kindt MV, Majka JA (1998) Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci 43:1009–1015

    Article  PubMed  CAS  Google Scholar 

  17. Lichtenberger LM, Romero JJ, Gibson GW, Blank MA (2000) Effect of bisphosphonate on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45:1792–1801

    Article  PubMed  CAS  Google Scholar 

  18. Furuta K, Ishihara S, Sato S, Miyake T, Ishimura N, Koshino K, Tobita H, Moriyama I, Amano Y, Adachi K, Ohta A, Kinoshita Y (2009) Development and verification of the Izumo Scale, new questionnaire for quality of life assessment of patients with gastrointestinal symptoms. Nihon Shokakibyo Gakkai Zasshi 106:1478–1487 (in Japanese)

    PubMed  Google Scholar 

  19. Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021

    Article  PubMed  Google Scholar 

  20. Perkins AC, Wilson CG, Frier M, Blackshaw PE, Dansereau RJ, Vincent RM, Wenderoth D, Hathaway S, Li Z, Spiller RC (2001) The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes water. Int J Pharm 222:295–303

    Article  PubMed  CAS  Google Scholar 

  21. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, Risedronate Phase III Research Group (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis; a comparison with 2.5 mg once-daily dosage regimen. J Bone Miner Metab 24:405–413

    Article  PubMed  CAS  Google Scholar 

  22. Dursun N, Dursun E, Yalcin S (2001) Comparison of alendronate, calcitonin and calcium treatment in postmenopausal osteoporosis. Int J Clin Pract 55:505–509

    PubMed  CAS  Google Scholar 

  23. Iwamoto J, Takeda T, Sato Y, Uzawa M (2004) Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol 23:383–389

    Article  PubMed  Google Scholar 

  24. Kakimoto S, Nagakura Y, Tamura S, Watabiki T, Shibasaki K, Tanaka S, Mori M, Sasamata M, Okada M (2008) Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X2/3 receptor function and exerts an analgesic effect in pain models. Eur J Pharmacol 589:98–101

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

We have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Orthopaedics, Sakamidorii Hospital, 6-28-1 Midorii, Asaminami-ku, Hiroshima, Hiroshima, 731-0103, Japan

    Toru Yoshioka

  2. Okimoto Clinic, 185-4 Kubi, Yutaka-machi, Kure, 734-0304, Japan

    Nobukazu Okimoto

  3. Okamoto Clinic, 7-5-26 Nukushina, Higashi-ku, Hiroshima, 732-0033, Japan

    Ken Okamoto

  4. Department of Orthopaedics, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan

    Akinori Sakai

Authors
  1. Toru Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobukazu Okimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akinori Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toru Yoshioka.

About this article

Cite this article

Yoshioka, T., Okimoto, N., Okamoto, K. et al. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients. J Bone Miner Metab 31, 153–160 (2013). https://doi.org/10.1007/s00774-012-0393-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-012-0393-x

Keywords

Search

Navigation